Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Sanofi-aventis, Covance to Partner on Drug Development

Covance Inc., a drug development services company in Princeton, New Jersey, announced today an agreement with French pharmaceutical company Sanofi-aventis to provide drug development services to Sanofi-aventis over the next 10 years, with payments ranging from $1.2 billion to $2.2 billion.

As part of the agreement, Sanofi-aventis will sell its Porcheville, France and Alnwick, United Kingdom sites and facilities to Covance for about $25 million, where Covance will maintain employment for at least the next five years. The companies plan to complete the transaction by the end of the year.

Under the agreement, Sanofi-aventis will get access to Covance’s services for discovery support, toxicology, chemistry, clinical trials, central laboratory, and market access, with annual commitments for these services increasing over the next decade. The deal also includes a 10-year sole-source relationship for central laboratory services.

Covance will acquire Sanofi-aventis’s chemistry, manufacturing, and control services with the addition of the Porcheville and Alnwick sites. These services include preformulation, drug formulation, radiolabeled chemistry, and preclinical and early-stage clinical active pharmaceutical ingredient manufacturing.

Comments are closed.